PMC7125505_01
Patient BCR-ABL1 levels throughout disease course.
CRIHEM2020-9571691.001.jpg
PMC7125505_01_CRIHEM2020-9571691.001.jpg
fig1
The patient achieved a major molecular response (MMR; BCR-ABL1/ABL1 IS <= 0.1% on the International Scale) at 16 months that was maintained for seven years (Figure 1). Thereafter, a deeper molecular response (MR4; BCR-ABL1/ABL1 IS <= 0.01% on the International Scale) was transiently noted. TKI, he preferred to pursue a trial of treatment cessation, prompting immediate monthly BCR-ABL1 monitoring to detect any loss of molecular response as per European guidelines. The patient is now 18 months after TKI discontinuation maintaining a stable BCR-ABL1 level of 0.01% (Figure 1) and remains clinically well.